BioStem Technologies to Present at Two Upcoming Investor Conferences
POMPANO BEACH, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that Company management will present at the following upcoming investor conferences being held in New York, NY.
Morgan Stanley Global Healthcare Conference:
- Format: Fireside Chat
- Date: Monday, September 8, 2025
- Time: 3:20 PM ET
H.C. Wainwright 27th Annual Global Investment Conference:
- Format: Presentation
- Date: Tuesday, September 9, 2025
- Time: 11:00 AM ET
Interested parties may access live and archived webcasts of the presentations on the “investors” section of the Company’s website at: .
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list , and follow us on and .
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on and .
Contact BioStem Technologies, Inc.:
Website:
E-Mail:
X:
Facebook:
Phone: 954-380-8342
Investor Relations:
Adam Holdsworth, BioStem Director of Investor Relations
E-Mail:
Phone: 917-497-9287
Or
Gilmartin Group
Philip Trip Taylor, Principal
E-Mail:
Phone: 415-937-5406
